Business Wire

Lattice Reinvents the Low Power, General-Purpose FPGA with New Certus-NX

24.6.2020 23:00:00 EEST | Business Wire | Press release

Share

Lattice Semiconductor Corporation (NASDAQ: LSCC), the low power programmable leader, today launched the new Lattice Certus™-NX family of FPGAs. The devices lead the general-purpose FPGA market in I/O density, delivering up to twice the I/O density per mm2 in comparison to similar competing FPGAs, and provide best-in-class power savings, small size, reliability, instant-on performance, and support fast PCI Express (PCIe) and Gigabit Ethernet interfaces to enable data co-processing, signal bridging, and system control. Certus-NX FPGAs target a range of applications, from data processing in automated industrial equipment to system management in communications infrastructure. The Certus-NX devices are the second family of FPGAs developed on the Lattice Nexus™ platform, the industry’s first low power FPGA platform using 28 nm FD-SOI process technology. With the launch of Certus-NX, Lattice marks the release of the second device family developed under Lattice’s new product development strategy in just six months.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200624005722/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

The new Certus™-NX Low Power, General Purpose FPGA from Lattice Semiconductor (Photo: Business Wire)

“Certus-NX delivers unique and innovative capabilities that set it apart,” said Linley Gwennap, Principal Analyst at The Linley Group. “Compared to competing FPGAs of similar gate counts, Lattice offers a much smaller package, greater I/O density, and lower power.”

“Thanks to innovations at the system, architecture, and circuit level in our Lattice Nexus development platform, we are releasing new products at a faster pace and giving our customers more options to choose from as they evaluate the performance and power needs of their applications,” said Gordon Hands, Director of Product Marketing, Lattice Semiconductor. “Certus-NX has clearly reset expectations for what developers should look for in general-purpose FPGAs by providing a compelling blend of parallel processing performance and flexible I/O support that enables creative new device designs.”

Technology trends like industrial automation and 5G have developers across markets looking to add processing and connectivity to applications that operate at the network Edge. To successfully support these trends, devices require low power processing hardware with support for popular interfaces like PCIe and Gigabit Ethernet. Device developers also need easy-to-use development platforms from a single source that provide the hardware, software, and IP they need to get products to market quickly.

“As an FPGA-centric design house, we’re seeing increasing adoption of serial protocols like PCIe and Gigabit Ethernet for chip-to-chip connectivity in many end applications, including 5G and IoT systems,” said Sanjeev Kumar, CEO, Logic Fruit Technologies. “The latest generation of FPGAs by Lattice, Certus-NX, supports these standards and provides a high density of I/Os while keeping power consumption and overall device footprint in check. These FPGAs will allow us to rapidly adapt to the challenging and evolving connectivity and performance needs of our customers.”

Key features of the Lattice Certus-NX FPGA family include:

  • Up to 3x smaller form factor – Certus-NX FPGAs easily fit into compact designs with minimal impact on overall design footprint. For example, Certus-NX FPGAs can enable a complete PCIe solution with a size of only 36 mm2. Even when using the smallest package available in the family, Certus-NX FPGAs deliver up to twice the I/O density per mm2 in comparison to similar competing FPGAs to enable greater design flexibility and robust support for bridging applications.
  • Robust I/O interfacing capability – Certus-NX developers will have access to Lattice’s extensive IP library. Notable IP blocks available on Certus-NX include:
    • 1.5 Gbps differential I/O with performance that is up to 70 percent higher than competing FPGAs.
    • 5 Gbps PCIe, 1.5 Gbps SGMII, and 1066 Mbps DDR3. Developers can test these IP blocks on Certus-NX development boards for the fast implementation of interfaces commonly used in Certus-NX FPGAs’ target applications.
  • Robust authentication and encryption – To secure the devices’ bitstream against unauthorized access/alteration/copying, Certus-NX FPGAs support AES-256 with ECDSA authentication to protect devices throughout their lifecycles. Currently, Certus-NX devices are the smallest FPGAs on the market to support ECDSA.

  • Up to 4x lower power consumption – Certus-NX FPGAs use a programmable back bias to enable user-selectable high performance or low power operating modes, depending on the needs of their application. The devices can provide power consumption up to 4x lower than similar FPGAs.
  • Instant-on performance – The devices also offer ultra-fast device configuration from SPI memory that is up to 12x faster than similar competing FPGAs, with individual I/Os able to configure in just 3 ms, and full-device startup in only 8-14 ms depending on device capacity.
  • High reliability – Reliable performance is key for safety-critical industrial and automotive applications where devices must perform as expected to avoid damage/injury. Certus-NX FPGAs offer up to 100 times better soft-error rate (SER) performance than similar FPGAs. Certus-NX FPGAs are temperature-rated for use in industrial applications. They also support ECC and SEC in hardware.
  • Ease of use/design – Certus-NX FPGAs support Lattice Radiant® software, an easy-to-use, unified FPGA design environment that integrates best-in-class tools and features to help users develop their applications quickly and efficiently.

Lattice has already shipped sample devices to select customers. For more information, please visit http://www.latticesemi.com/Certus-NX.

About Lattice Semiconductor

Lattice Semiconductor (NASDAQ: LSCC) is the low power programmable leader. We solve customer problems across the network, from the Edge to the Cloud, in the growing communications, computing, industrial, automotive, and consumer markets. Our technology, long-standing relationships, and commitment to world-class support lets our customers quickly and easily unleash their innovation to create a smart, secure and connected world.

For more information about Lattice, please visit www.latticesemi.com. You can also follow us via LinkedIn, Twitter, Facebook, YouTube, WeChat, Weibo or Youku.

Lattice Semiconductor Corporation, Lattice Semiconductor (& design) and specific product designations are either registered trademarks or trademarks of Lattice Semiconductor Corporation or its subsidiaries in the United States and/or other countries. The use of the word “partner” does not imply a legal partnership between Lattice and any other entity.

GENERAL NOTICE: Other product names used in this publication are for identification purposes only and may be trademarks of their respective holders.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

MEDIA CONTACT:
Bob Nelson
Lattice Semiconductor
408-826-6339
Bob.Nelson@latticesemi.com

INVESTOR CONTACT:
Rick Muscha
Lattice Semiconductor
408-826-6000
Rick.Muscha@latticesemi.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release

Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o

Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a

DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye